If you or someone you know has tried antidepressant after antidepressant and found little or no relief, you are not alone — and for the first time in decades, the treatment landscape is genuinely expanding. For the roughly one-third of the 21 million Americans diagnosed with major depressive disorder who do not respond adequately to standard antidepressants, 2026 is bringing the most significant shift in available treatment options in a generation.
Two developments are redefining what is possible for this underserved population. First, new Phase 3 clinical data published in January 2026 confirmed that Caplyta (lumateperone), taken alongside a traditional antidepressant, nearly doubled the likelihood of achieving full remission at six weeks compared to placebo. Second, Spravato (esketamine), the FDA-approved nasal spray, is now available as a standalone monotherapy — meaning some patients with treatment-resistant depression may now be able to achieve relief without requiring a daily oral antidepressant at all.
What the Caplyta Data Shows
Caplyta (lumateperone), manufactured by Intra-Cellular Therapies and studied in clinical trials supported by Johnson & Johnson, is a novel antidepressant adjunct that works through a different mechanism than standard SSRIs and SNRIs. It modulates serotonin, dopamine, and glutamate activity simultaneously — a multi-pathway approach distinct from any previously approved antidepressant.
In a pooled analysis of two Phase 3 randomized controlled trials, presented at the 2026 American College of Neuropsychopharmacology Annual Meeting in January, 65 percent of patients taking Caplyta plus an antidepressant achieved remission at six weeks, compared with those on placebo plus antidepressant. More importantly, 43 percent of Caplyta-treated patients achieved sustained remission over a six-month study period — a durability result that is unusually strong for adjunctive antidepressant therapies.
Caplyta was already FDA-approved for bipolar depression. The new data specifically supports its use as an add-on therapy for major depressive disorder — a distinct and much larger patient population.
Spravato as a Standalone Treatment for TRD
In January 2025, the FDA approved Spravato (esketamine) nasal spray as the first and only standalone monotherapy for adults with major depressive disorder who have not adequately responded to at least two oral antidepressants. Prior to this approval, Spravato was only indicated for use alongside an oral antidepressant — a combination requirement that created barriers for patients who could not tolerate or did not respond to oral medications.
With the monotherapy approval, clinicians can now prescribe Spravato alone to eligible patients. The drug works by blocking NMDA receptors in the brain — a mechanism entirely distinct from standard SSRIs and SNRIs. Clinical trial data demonstrated improvement in depressive symptoms as early as 24 hours after the first dose, with sustained benefit at 28 days. That rapid onset is clinically meaningful for patients in acute distress and for those who have waited years for effective treatment.
Spravato is administered as a nasal spray in a certified healthcare provider's office, where patients are monitored for two hours after each dose. Treatment is typically twice weekly for four weeks, then weekly or biweekly as a maintenance schedule. The drug carries a risk of dissociation, dizziness, and nausea — which is why in-office administration and monitoring are required.
What Patients Should Know
Both treatments are available now for appropriate patients and can be discussed with a psychiatrist or primary care physician. Neither is a first-line treatment — both are specifically for patients who have already tried and not responded adequately to standard antidepressants. A psychiatrist can evaluate whether either option is appropriate based on a patient's clinical history, prior treatment trials, and medical profile.
For Americans who have been struggling with depression that has not responded to standard medications, the message from the clinical data in 2026 is encouraging: the options available today are genuinely broader, more mechanistically diverse, and more evidence-supported than at any previous time in the history of depression treatment.
If you are experiencing depression and have not found adequate relief from standard treatment, the first step is speaking openly with your physician about the specific medications you have tried and their effects. An honest account of prior treatment history is the foundation for determining whether a different therapeutic approach — including newer options — might be appropriate.
Frequently Asked Questions
Q: What is treatment-resistant depression?
A: Treatment-resistant depression (TRD) is defined as major depressive disorder that has not responded adequately to at least two different antidepressant medications at adequate doses and durations. It affects approximately one-third of people diagnosed with MDD.
Q: What did the new Caplyta study find?
A: Phase 3 data presented at the January 2026 ACNP Annual Meeting found that 65 percent of patients taking Caplyta as an add-on to their antidepressant achieved remission at six weeks — nearly double the remission rate compared to placebo plus antidepressant.
Q: What is Spravato and how does it work?
A: Spravato (esketamine) is an FDA-approved nasal spray that blocks NMDA receptors in the brain. It is now approved as a standalone treatment for adults with TRD. It can produce improvement in depressive symptoms as early as 24 hours after administration.
Q: Are these treatments available right now?
A: Yes. Both Caplyta (for adjunctive use in MDD) and Spravato (as standalone TRD monotherapy) are currently FDA-approved and available through psychiatrists and certified healthcare providers.
Q: Who should consider these treatments?
A: Patients who have tried and not responded adequately to at least two antidepressants should speak with a psychiatrist about whether these or other newer treatment options might be appropriate for their specific situation.
